Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

Author's Avatar
Nov 07, 2022

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.